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Introduction
Human microbiome estimation in various areas 
of our body is becoming more and more important 
for the knowledge of the saprophytes genomes that 
inhabit on our external surfaces and on the mucosal 
tissues open to the outside. This has reached even 
more importance when the study is compared with 
the pathological aspects of the various diseases that 
may occur to those different sites. In particular, it is 
obvious that, inside the body, there are less accessible 
organs, through lined up by mucosal tissue open to 
the outside, that are often too much invasive to be 
reached, but they may be important to be analyzed 
for pathological aspects among which the microbi-
ome is an important aspect for several pathological 
situations.
In this context, lower airways are certainly sites 
that can be reached by an invasive procedure through 
a bronchoscopy approach and also by collecting in 
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that situation the bronchoalveolar lavage (BAL) 
fluid. By this approach, the BAL fluid may be ana-
lyzed for its content, including the microbiome, and 
compared with several pathological situations where 
signatures may be taken both to compare with nor-
mal ones and among them, and also to establish sig-
natures at level of microbiome that can be used for 
indicating or contribute to the clinical diagnosis as, 
for instance, in pulmonary sarcoidosis.
Sarcoidosis is a chronic granulomatous disor-
der characterized by multi-organ system impairment 
that mainly affects the lungs (1, 2). The typical, al-
though not specific, histological finding of sarcoido-
sis is the presence, within affected tissues, of epithe-
liod granulomas with inflammatory infiltration (1). 
Clinical signs are extremely variable depending on 
the extent of the inflammatory lesions and on the 
kind of tissues affected (1). In the most severe forms, 
it can evolve to respiratory insufficiency, severe neu-
rologic impairments, blindness and sudden cardiac 
death (2). 
The etiopathogenesis of sarcoidosis is not well 
established. The currently accepted hypothesis is 
that, in genetically predisposed (both HLA and non-
HLA) subjects, a persistent host immune response 
occurs against a specific antigen; viral infections have 
been implicated in the development of sarcoidosis, 
although their specific role remains to be established 
(3-12).
In recent years, next-generation sequenc-
ing technologies (NGS) have given an impulse to 
metagenomics (13-15). These approaches, in addi-
tion to the sequence of the entire genome of specific 
microorganisms (16, 17), by enabling the simultane-
ous study of all the genomes of a microbial commu-
nity directly recovered from specific environments, 
have many advantages over more traditional tech-
niques (14, 15). They have already been successfully 
used to identify the composition of microbial com-
munities in different ecosystems and to characterize 
specific human microbial niches, also in relation to 
different diseases (18-21). Notably, a NGS-based 
approach has recently been used to investigate the 
microbial communities of the upper and lower air-
ways of patients affected by different respiratory dis-
eases (22-27). 
Here, we describe the use of a multiplexed 16S 
rRNA amplicon-based approach, coupled with NGS 
analysis, to characterize the lower airway microbiota 
of patients with interstitial lung diseases to deter-
mine whether bacterial dysbiosis is disease-specific, 
and the difference with higher airways chronic res-
piratory diseases.
Materials and methods 
Patients’ enrollment and clinical features
Nineteen unrelated subjects were enrolled in 
this study among patients attending the Respiratory 
Section of the University Federico II of Naples, Italy. 
Subjects underwent bronchoscopy for a diagnostic 
purpose and were diagnosed, with a multidiscipli-
nary approach, as pulmonary sarcoidosis (PS, 10 pa-
tients), or interstitial lung disease (ILD, 9 patients), 
(see table 1). In particular, in such a last group, 6 were 
nonspecific idiopathic pneumonia (NSIP), and 3 
were idiopathic pulmonary fibrosis (IPF): all of them 
were recently diagnosed (1-2 months), whereby no 
treatment was administered. In the first group (PS), 
most of patients were classified as stage 1 (7), where 
only 3 were assigned to stage 2. 
Inclusion criteria were: no use of antibiotics, an-
tivirals or corticosteroids for at least 2 weeks before 
sampling, no use of probiotics in the 2 months before 
sampling, no recent bacterial/viral respiratory tract 
infections 2 weeks before sampling. Notably, we did 
not enroll a control group of healthy subjects because 
Table 1. General features (clinical and instrumental data) of the 
study population
 Groups
 PS ILD
N. of subjects 10 9
Age, years (mean±SD) 57±10 64±11
Sex F/M 4F/6M 3F/6M
Clinical diagnosis Sarcoidosis Interstitial lung
  diseases
FVC % (range; mean±SD) 71-98; 94.2±15.6 42-88; 63.8±28.8
DLCO % (range; mean±SD) 25-85; 66.7±17.5 34-75; 54.3±15
Recent infections 0/10 0/9
Probiotics assumption 0/10 0/9
Immunosuppressive therapy (N) 1/10  0/9
Corticosteroid therapy (N) 2/10  1/9
PS, pulmonary sarcoidosis patients; ILD, interstitial lung diseases; 
SD, standard deviation; F, female; M, male; FVC, forced vital ca-
pacity; DLCO, diffusing capacity of the lung carbon monoxide; 
N, number
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of the invasiveness of the BAL procedure for which 
also the Ethics Committee did not allowed. All pa-
tients gave their written informed consent to the 
study; the study was approved by the Ethics Com-
mittee of the Ospedale dei Colli, Naples, Italy, to 
which the mentioned Respiratory Section belongs.
Sample collection, DNA extraction and 16S rRNA 
sequencing
A BAL sample was collected from each sub-
ject during bronchoscopy. An aliquot was used for 
standard diagnostic evaluations (including tradi-
tional microbiological assessment) and an aliquot 
was immediately cooled in ice and stored at -80°C 
for metagenomic analysis. DNA was extracted from 
BAL (600 μl/sample) using the QIAamp DNA 
mini Kit (Qiagen,Venlo, Netherlands) following 
manufacturer’s instructions. V4-V6 hypervariable 
regions of the bacterial 16S rRNA gene were am-
plified using a specific primer pair (forward prim-
er: 5’-CAGCAGCCGCGGTAATAC-3’; reverse 
primer: 5’- TGACGACAGCCATGC-3’), as we 
previously described (28). Sequence data analysis 
was carried out using the specific metagenomic tool 
QIIME, v. 1.8.0 (29, 30). A pre-quality filtering step 
was conducted in QIIME using suitable parameters 
for 454 sequencing. For a sequence to be retained, the 
following criteria had to be met: (i) a minimum aver-
age quality Phred score of 25; (ii) a minimum and 
maximum sequence length (200-1000, 454 data set); 
(iii) no more than six ambiguous bases or homopoly-
mers. A total of 387,357 sequences passed the qual-
ity-filtering step (mean: 21,519; Stdev: 13,523), and 
were clustered to obtain OTU using a subsampled 
open-reference OTU picking approach. The OTU 
picking procedure was computed with UCLUST (at 
97% identity) using the 16S rRNA GREENGENES 
database (v. 13_8) as a reference database (31, 32). 
Sequences that did not match the GREENGENES 
database were clustered as de novo as to not lose the 
overall novel diversity. Taxonomic assignment was 
also computed using UCLUST with a 0.9% similar-
ity against a representative set of 16S rRNA gene 
sequences from the GREENGENES database. A 
phylogenetic tree was obtained using PyNAST (33) 
and used for downstream phylogenetic analysis. The 
alpha and beta diversity analyses were computed at a 
rarefaction depth of 8,031 sequences/sample. Alpha 
diversity was computed for each rarefied OTU table, 
using the number of observed species metric and the 
Faith’s Phylogenetic Diversity Index. Beta diversity 
was performed using weighted and unweighted Uni-
Frac distance matrices and plotted as principal coor-
dinate analysis (PCoA) in Emperor (34). Taxonomic 
assignment was done, within the bacteria kingdom, 
according to hierarchical classification from phylum 
down to genus.
Statistical analysis 
Quantitative differences in the relative abun-
dance of each identified taxa within the two groups 
were evaluated using specific QIIME scripts based 
on Kruskal Wallis non-parametric ANOVA for the 
analysis of variance with both Bonferroni and FDR 
corrections (p≤0.05 after correction indicates signifi-
cant differences). Alpha diversity significance was as-
sessed using a non-parametric two-sample t-test to 
compare the alpha diversities for both metrics (i.e. 
Phylogenetic diversity “PD” and number of observed 
OTUs) using 999 Monte Carlo permutations. P-
values were adjusted using Bonferroni correction to 
show any difference between the compared groups. 
Beta diversity was analyzed through the two differ-
ent statistical tests ADONIS and ANOSIM using 
UniFrac distance matrices (35, 36).
 
Results
Bronchoalveolar lavage samples from the 19 en-
rolled patients were analyzed for their microbial qual-
itative and quantitative richness, as described under 
Methods. Traditional microbiological evaluation did 
not reveal any positive cultures in any patient. Next, 
we carried out a pyrosequencing NGS run of all 
samples to analyze the entire study population, and 
obtained more than 400,000 sequences that resulted 
in an average of 21,878 high quality mapped reads/
sample. Taxonomic assignment of reads revealed 18 
phyla, of which 10 at an abundance ≥0.1% (fig. 1). 
Of the phyla present in all patients, the most repre-
sented were Bacteroidetes, Firmicutes, Fusobacteria 
and Proteobacteria, of which the relative abundances 
were respectively 70%, 10%, 3% and 15.5%. Bacte-
rial composition was similar in all patients except in 
a patient affected by interstitial lung disease (ILD). 
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The microbiome profile of this patient (ILD9) was 
dominated by the Proteobacteria phylum; its pecu-
liar profile remains down to genus level where the 
Moraxella genus represents 98.4% of all the bacte-
rial communities. This profile may have resulted from 
an acute occasional infection, which rarely invades 
the lung from the upper airways. Given its extreme 
peculiarity we did not include it in the downstream 
comparison between the study groups.
Figure 2 illustrates the composition of the mi-
crobial communities in the two groups of patients 
studied. The taxonomic assignment did not reveal 
any significant differences between patients affected 
PS and patients affected by ILD. Four phyla were 
present at a relative abundance >1%: Bacteroidetes, 
Proteobacteria, Firmicutes and Fusobacteria. Bacte-
roidetes was the most abundant in both groups with 
an average relative abundance of about 56.9% (fig. 
2A, B). The relative abundance of different bacteria 
remained unchanged down to genus level. In detail, 
within the Bacteroidetes phylum, we found going 
from class to genus level, a high level of (1) Bacte-
roidia (class level, 55.5% average relative abundance); 
(2) Bacteroidales (order level, 55.5% average relative 
abundance); (3) Prevotellaceae, [Paraprevotellaceae] 
and Porphyromonadaceae (family level, 42.5%, 8.4% 
and 4.5% average relative abundance, respectively); 
and (4) Prevotella, [Prevotella] and Porphyromonas 
(genus level, 42.5%, 8.4% and 4.4% average relative 
abundance, respectively) (fig. 2C). Firmicutes and 
Proteobacteria were also represented in the lower 
airway microbiota of the two groups. 
At genus level, the average relative abundance 
of Streptococcus, (belonging to Firmicutes) was 6.1%, 
while the average relative abundances of Neisseria 
and Haemophilus, (belonging to Proteobacteria) were 
7.5% and 4%, respectively (fig. 3). 
Further, we used alpha diversity, as computed 
with Faith’s Phylogenetic (fig. 4A) and OTUs (fig. 
4B) diversity indices to evaluate bacterial commu-
nity diversity, and found no differences in bacterial 
community richness between PS and ILD patients. 
However, the number of bacterial taxa was lower, al-
beit not significantly so, in PS patients than in ILD 
patients (fig. 4A,B). Beta diversity, namely, global 
community differences, was inferred using both 
unweighted (quantitative) (fig. 4C) and weighted 
(qualitative) (fig. 4D) UniFrac distances matrices. 
The resulting PCoA plots did not reveal any statis-
tical difference between the two groups. In fact, in 
the PCoA plots, patients were randomly distributed 
when samples were clustered by disease status. 
Fig. 1. Microbial communities identified in the 18 subjects at phylum level using 16S rRNA pyrosequencing and QIIME taxonomic assign-
ment. The specific bacterial distribution of each study subject at phylum level; each bar represents a study subject. Different phyla are assigned 
to specific colors; Bacteroidetes phylum results the most represented one in the whole set of subjects
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Discussion
Various studies have suggested that infec-
tion can cause PS and identified different potential 
disease-causing bacteria (37-42). In detail, myco-
bacterial DNA has been identified in different PS 
samples, such as lung biopsies, formalin-fixed par-
affin-embedded tissues (37), lymph nodes (38), lung 
tissue and bronchial lavage fluid (39). All these stud-
ies performed polymerase chain reaction (PCR) to 
detect mycobacterial DNA in clinical samples from 
patients with sarcoidosis. Similarly, the presence of 
Propionibacterium acnes was demonstrated in tissue 
samples of PS patients using bacterial cultures (40), 
whereas antibodies against P. acnes have been iden-
tified in BAL fluid (41). Recently, propionibacterial 
rRNA was identified through real-time quantita-
tive reverse transcription-polymerase chain reaction 
in formalin-fixed and paraffin-embedded tissue of 
lymph node biopsies, and thus proposed as a poten-
tial biomarker of sarcoidosis (42). 
Thanks to advances in meta-omics technologies, 
it is now possible to analyze microbial communities 
in their integrity (13-15). Consequently, the focus 
has shifted from a single bacterial infection to a more 
general alteration of microbial communities. It seems 
that modifications of the mutual relationship among 
microbial species in a specific environment, as well as 
the alteration in microbiome composition (i.e., dys-
biosis), can affect host physiology. This, in turn, leads 
to disease development or at least it might trigger the 
pathogenesis of more complex diseases. Therefore, 
we used a NGS-based 16S rRNA approach to fully 
characterize the pulmonary microbiota in the lower 
airways, and to evaluate whether dysbiosis is specific 
to a given disease, e.g., PS. The lower airway micro-
biota of patients affected by interstitial lung disease, 
including a small number of sarcoidosis patients, 
have been previously identified and no differences 
in terms of the composition of microbial communi-
ties able to discriminate the different diseases were 
found (23). Interestingly, in this paper Prevotellaceae 
and Streptococcaceae were the most represented taxa at 
family level; similarly, irrespective of disease etiology, 
Prevotellaceae was the most abundant family also in 
our datasets, with Prevotella being the most repre-
sented bacterial genus in BAL fluid. Conversely, in 
the same paper, differences between the upper and 
lower airway microbiota where identified, suggesting 
that a microbial discontinuity could be present, go-
ing from the upper to lower airways. In our study, we 
focused on PS in order to study a more homogene-
ous group of patients, and fully characterized their 
microbiota versus a group of patients affected by a 
variety of chronic inflammatory diseases. We found 
Fig. 2. The composition of the lower airway microbiota identified 
in interstitial lung diseases (ILD) and pulmonary sarcoidosis (PS) 
patients, from phylum to genus level (from center to peripheral 
ring). Krona plots show the hierarchical taxonomic distribution in 
each ring from phylum to family. Taxonomic assignment shows no 
significant differences between the two studied groups. Bacteroi-
detes was the most represented phylum with an average relative 
abundance of 70% in the entire population both in ILD (A) and 
PS (B) subjects. Percentages are normalized relative abundances of 
bacteria observed only in the most abundant phyla (>1%)
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that the microbiota of PS patients does not have a 
specific signature able to discriminate sarcoidosis 
from other chronic respiratory diseases of the lower 
airways. Consequently, patients affected by diverse 
chronic respiratory diseases seem to share the same 
signature. 
We may acknowledge that a limitation of our 
study is the rather limited number of subjects in-
cluded in each group. This mainly depends on two 
factors. First, sarcoidosis, a relatively rare disease, 
has a high phenotype variability. Thus, to obtain a 
more homogenous sample, we included only patients 
with pulmonary signs, in wash-out from corticos-
teroids, and undergoing a bronchoscopy procedure. 
The second issue is the difficulty in enrolling healthy 
subjects as control group due to the invasiveness of 
sampling procedures. Therefore, we enrolled only pa-
tients who required a bronchoscopy for the diagnosis 
or monitoring of their specific lung disease. Further-
more, we excluded subjects with recent or ongoing 
infections at the time of examination to avoid bias 
in the microbiome evaluation. In addition, we ana-
lyzed the patients’ microbiome using non-parametric 
approaches (e.g., adonis, ANOSIM) based on per-
mutation testing (e.g., Monte Carlo), which are fre-
quently used to establish the effect size of a particu-
lar condition on the microbiome composition as well 
as to perform rarefaction analysis to limit sampling 
variability (43, 44). Given our statistical evaluations, 
the results are highly reproducible also when applied 
to higher numbers of samples (45, 46). The use of 
power analyses and/or parametric models, as applied 
to metagenomic amplicon studies, is new and cur-
rently under investigation (45, 46), therefore we used 
a more conservative approach based on multiple rar-
efaction curves. 
Globally, our results suggest the absence of a 
qualitative and/or quantitative microbial signature in 
the lower airway microbiota able to specifically dis-
criminate PS from other interstitial lung diseases. In 
addition, our findings are in line with other studies 
that did not identify distinct microbial signatures in 
different respiratory diseases (23, 47). Taken togeth-
er, our results suggest that, unlike other body sites, 
the microbiome of BAL from lower airways is prac-
tically stable and not influenced in its qualitative and 
quantitative composition by different pathological 
processes that induce respiratory impairment.
In conclusion, our study shows that there is a 
similar microbiome signature in the BAL fluid of pa-
Fig. 3. Genus-level comparison of BAL microbial communities among the two study groups showed no differences in microbial composition 
among interstitial lung diseases (ILD) and pulmonary sarcoidosis (PS) patients. At genus level, we found the prevalence of members of the 
Bacteroidetes phylum being Prevotella (42.5%) and [Prevotella] (8.4%) the most abundant genera. Members of the Firmicutes and Proteo-
bacteria phyla were also represented in both groups; Streptococcus (Firmicutes), Neisseria and Haemophilus (both within Proteobacteria) genera 
were respectively the most abundant within these two groups of patients, even if at a rather low level
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tients affected by different interstitial lung diseases 
of the lower airways. However, similar analyses are 
required to determine the possible effect of viruses 
and fungi populations in these pulmonary diseases.
Fig. 4. Lower airway microbiota diversity analysis. Alpha diversity of microbial communities was measured using Faith’s phylogenetic di-
versity index (A) and the number of observed OTUs (B). The error bars represent standard error of the mean. In addition, beta diversity 
was also computed using the Principal Coordinates Analysis (PCoA) with both unweighted (C) and weighted (D) UniFrac distances. No 
statistical significance was observed when samples were grouped by disease status, which also showed a very low effect size on the microbiome 
composition.
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